Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – A view from the IFCC Working Group for PTH

Sturgeon, Catharine M, Sprague, Stuart, Almond, Alison, Cavalier, Etienne, Fraser, William D, Algeciras-Schimnich, Alicia, Singh, Ravinder, Souberbielle, Jean-Claude and Vesper, Hubert W and IFCC Working Group for PTH (2017) Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – A view from the IFCC Working Group for PTH. Clinica Chimica Acta, 467. pp. 42-47. ISSN 0009-8981

[thumbnail of Accepted manuscript]
PDF (Accepted manuscript) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (553kB) | Preview


Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of calcium/phosphate disorders, and is widely used as a surrogate marker to assess skeletal and mineral disorders associated with chronic kidney disease (CKD), referred to as CKD-bone mineral disorders (CKD-MBD). CKD currently affects >10% of the adult population in the United States and represents a major health issue worldwide. Disturbances in mineral metabolism and fractures in CKD patients are associated with increased morbidity and mortality. Appropriate identification and management of CKD-MBD is therefore critical to improving clinical outcome. Recent increases in understanding of the complex pathophysiology of CKD, which involves calcium, phosphate and magnesium balance, and is also influenced by vitamin D status and fibroblast growth factor (FGF)-23 production, should facilitate such improvement. Development of evidence-based recommendations about how best to use PTH is limited by considerable method-related variation in results, of up to 5-fold, as well as by lack of clarity about which PTH metabolites these methods recognise. This makes it difficult to compare PTH results from different studies and to develop common reference intervals and/or decision levels for treatment. The implications of these method-related differences for current clinical practice are reviewed here. Work being undertaken by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to improve the comparability of PTH measurements worldwide is also described.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:
Depositing User: Pure Connector
Date Deposited: 16 Dec 2016 00:07
Last Modified: 19 Oct 2023 01:53
DOI: 10.1016/j.cca.2016.10.016


Downloads per month over past year

Actions (login required)

View Item View Item